Evidence map›Paper›PMID 37530525›Full record

ArticlemBio2023

The largest HIV-1-infected T cell clones in children on long-term combination antiretroviral therapy contain solo LTRs.

Johannes C Botha, Dimiter Demirov, Carli Gordijn, Mary Grace Katusiime, Michael J Bale, Xiaolin Wu, Daria Wells, Stephen H Hughes, Mark F Cotton, John W Mellors and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Johannes C BothaStellenbosch University , Cape Town, South Africa.ORCID 0000-0002-7635-7810
Dimiter DemirovCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research , Frederick, Maryland, USA.
Carli GordijnStellenbosch University , Cape Town, South Africa.
Mary Grace KatusiimeHIV Dynamics and Replication Program, National Cancer Institute , Frederick, Maryland, USA.
Michael J BaleLaboratory of Epigenetics and Immunity, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine , New York, New York, USA.
Xiaolin WuHIV Dynamics and Replication Program, National Cancer Institute , Frederick, Maryland, USA.
Daria WellsHIV Dynamics and Replication Program, National Cancer Institute , Frederick, Maryland, USA.
Stephen H HughesHIV Dynamics and Replication Program, National Cancer Institute , Frederick, Maryland, USA.
Mark F CottonStellenbosch University , Cape Town, South Africa.
John W MellorsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania, USA.
Mary F KearneyHIV Dynamics and Replication Program, National Cancer Institute , Frederick, Maryland, USA.
Gert U van ZylStellenbosch University , Cape Town, South Africa.
National Cancer Institute · USStellenbosch University · ZACornell University · USLeidos (United States) · USUniversity of Pittsburgh · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
I4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0M
Combined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6M
Dynamics and Genetics of HIV Proviruses Before and During Antiretroviral TherapyZIABC011681 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KEARNEY, MARY · 2016 to 2025
$9.3M
Understanding Immune Evasion by HIV-1 RepliclonesR01AI165031 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HALVAS, ELIAS K. · 2021 to 2025
$3.6M
Characterizing HIV-1 diversity, evolution, and integration sites in children initiating cART in early infectionU01CA200441 · NCI · STELLENBOSCH UNIVERSITY · PI KEARNEY, MARY, VAN ZYL, GERT UVES · 2015 to 2019
$842k
NCI NIH HHS 75N91019D00024NCI NIH HHS U01 CA200441NIAID NIH HHS R01 AI165031NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI126603NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164565
6 · The paper itself

Abstract

Combination antiretroviral therapy (cART) suppresses viral replication but does not cure HIV infection because a reservoir of infectious (intact) HIV proviruses persists in long-lived CD4+T cells. However, a large majority (>95%) of HIV-infected cells that persist on effective cART carry defective (non-infectious) proviruses. Defective proviruses consisting of only a single LTR (solo long terminal repeat) are commonly found as endogenous retroviruses in many animal species, but the frequency of solo-LTR HIV proviruses has not been well defined. Here we show that, in five pediatric donors whose viremia was suppressed on cART for at least 5 years, the proviruses in the nine largest clones of HIV-infected cells were solo LTRs. The sizes of five of these clones were assayed longitudinally by integration site-specific quantitative PCR. Minor waxing and waning of the clones was observed, suggesting that these clones are generally stable over time. Our findings show that solo LTRs comprise a large fraction of the proviruses in infected cell clones that persist in children on long-term cART. IMPORTANCE This work highlights that severely deleted HIV-1 proviruses comprise a significant proportion of the proviral landscape and are often overlooked.

Indexed as

HIV-1HIV InfectionsHIV SeropositivityAnimalsAntiretroviral Therapy, Highly ActiveCD4-Positive T-LymphocytesClone CellsHIV Long Terminal RepeatProvirusesHIVHIV cell clonesproviral quantificationprovirussolo LTR

Identifiers

PMID37530525
PMCPMC10470503
OpenAlexW4385477301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.